Deliberate AI

🎉 Exciting news: $20M awarded to our world-class consortium, led by Mount Sinai Health System, to Transform Mental Healthcare through AI Innovation! We at Deliberate AI are thrilled to announce our participation in a word-class consortium (PREDiCTOR) led by the Mount Sinai Health System, in partnership with IBM Research, Harvard University, John Hopkins University, Columbia University, and Carnegie Mellon University. Our groundbreaking project has been awarded a $20 million grant from the National Institute of Mental Health (NIMH) as part of the IMPACT-MH initiative (Individually Measured Phenotypes to Advance Computational Translation in Mental Health) 🚀 PREDiCTOR is a significant stride toward validating our technology in clinical care, in addition to our breakthrough AI-COA (in FDA ISTAND, https://lnkd.in/gtRQw3-X) and biomarker work (e.g. DARPA-funded Suicide Prevention, https://lnkd.in/e-B2j7f7) . At Deliberate AI, we are dedicated to transcending traditional care paradigms to empower both clinicians and patients within the mental health space. Our purpose is rooted in three transformative shifts we're working on: Advanced Diagnostics and Monitoring, Ambient Clinical Intelligence, and Precision Therapy Enablement. This initiative will accelerate the journey toward a future where mental health care is proactive, personalized, and profoundly effective. 🧠 About PREDiCTOR: Mental healthcare faces significant challenges due to the lack of objective behavioral assessment tools leaving clinicians to rely on subjective impressions, limiting individualized prognoses and treatment plans. PREDiCTOR aims to change this by a step-change addition beyond the typical data captured in the electronic health record (EHR); tapping into ambient audiovisual data from clinical encounters (🗣️: e.g., spoken language, eye contact, and facial expressions from patients and clinicians) and smartphone data (📱: e.g., information on physical activity, geolocation, social interactions, and sleep patterns.) By fusing these data modalities using advanced AI and machine learning, and a large longitudinal transdiagnostic sample of over 2100, we aim to develop clinical signatures that predict key outcomes in young individuals aged 15 to 30, such as treatment engagement, emergency room visits, and hospitalizations. This work aligns with the Biden-Harris Administration's commitment to addressing the mental health crisis, and IMPACT-MH was highlighted in a recent announcement (https://lnkd.in/eesrkQ_3) by The White House. The recognition by the NIMH award underscores the national importance of our efforts. 🙏 We extend our deepest gratitude to our amazing partners and the community committed to improving mental health care. Together, we're paving the way for a brighter future for the next generation. #MentalHealthInnovation #AIforGood #YouthWellness #HealthcareTransformation #IMPACTMH #PREDiCTOR #EthicalAI

🚀 Exciting News! 🚀 We're thrilled to unveil our latest initiative: INSYTE Integrated Systems for Treatment Evaluation: a real world multimodal data collection effort led by physician scientists 💡 Join us in building real-world datasets to guide evidence based practice and improve patient outcomes. Benefits for Clinicians: *Free access to the Deliberate platform for automated note transcription, PROs and beta testing cutting-edge AI outcome measures *Network and connect with other leaders in the field *Studies sponsored by the NIH, FDA and our industry partners Visit our website to learn more and sign up to stay updated on our progress. Plus, meet us at booth 506 at the APA Convention to learn more about INSYTE and our innovative solutions! https://lnkd.in/evFGxtiM #APAAM2024

Come hear our Medical Product Director, Rachna Saralkar, MD, MS speak about our work on ambient multimodal AI for mental at HealthNext Summit next week!

We’re honored to be recognized in the ’10 Companies to Watch’ on this year’s Digital Health 100, which highlights the most exciting and innovative HealthTech startups in New York. See the full list in the 2024 New York Healthcare Innovation Report: https://bit.ly/482oSgA #DH100

Grateful for HITLAB's ongoing support in our mission to empower mental health care through precision, empathy, and innovation.

Thanks for covering this milestone Fierce Biotech, Andrea Park https://lnkd.in/eUTpcBKE

Great to read coverage of our FDA ISTAND milestone on Law360, Beth JoJack 🙏 https://lnkd.in/gbYRZsgB

Our FDA Milestone! FDA announces that Deliberate’s AI-COA™ is Part of ISTAND Program, Breaking New Ground in AI and Mental Health! 📄 Read our press release: https://bit.ly/3S6cZjC 📄 Read FDA press release: https://bit.ly/3Hz2Nvj We're thrilled to announce a groundbreaking milestone for Deliberate AI: Our first AI-COA™ model, for Depression and Anxiety measurement, has been officially included in the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. This is not just a win for us; it's a pioneering moment in AI/ML, Digital Health Technology (DHT), and the fields of Psychiatry and Neuroscience. 💊 Advancing Pharma: Our cutting-edge MultiModal AI platform is set to transform psychiatric drug development and evaluation. By quantitatively capturing mental health symptoms, our AI-COA™ models offer a consistent, bias-free assessment, enhancing the precision and reliability of clinical trials. This means significantly more powerful, efficient, and faster drug development processes, leading to improved patient care and significant public health advancements. 🙏 Heartfelt Thanks: A huge shoutout to our talented team at Deliberate AI, past and present -- your hard work and dedication have made this possible. Also, a special thanks to leading experts in the field, Maurizio Fava and René S. Kahn MD, PhD, for their statements emphasizing the significance of this milestone. 💼 To Our Investors and Future Partners: This achievement exemplifies our potential for growth and scalability in the clinical trials and healthcare sectors. Deliberate AI is not just innovating; we're leading the way in AI for mental health. We're enabling 3 transformative and reinforcing shifts: Advanced Diagnostics and Monitoring, Ambient Clinical Intelligence and Precision Therapy Enablement. Let’s connect to explore how we can drive the future of mental health together. 👀 Stay Tuned: The inclusion of AI in drug development and healthcare is just starting, as is our journey. Follow us here on LinkedIn and sign up for our newsletter to not miss out on more exciting updates coming soon! 📩 Newsletter Sign-Up: https://bit.ly/3SI0NYd 🤝 Join the Conversation: What do you think the future holds for AI in healthcare? What are some of your questions and considerations of the use of AI in late-stage Clinical Trials? Share your thoughts below! #DigitalHealth #HealthTech #Medtech #Multimodal #AI #PharmaInnovation #ClinicalTrials #Depression #Anxiety #AIEthics ##AIinHealthcare

Our FDA Milestone! FDA announces that Deliberate’s AI-COA™ is Part of ISTAND Program, Breaking New Ground in AI and Mental Health! 📄 Read our press release: https://bit.ly/3S6cZjC 📄 Read FDA press release: https://bit.ly/3Hz2Nvj I’m thrilled to announce a groundbreaking milestone for Deliberate AI: Our first AI-COA™ model, for Depression and Anxiety measurement, has been officially included in the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. This is not just a win for us; it's a pioneering moment in AI/ML, Digital Health Technology (DHT), and the fields of Psychiatry and Neuroscience. 💊 Advancing Pharma: Our cutting-edge MultiModal AI platform is set to transform psychiatric drug development and evaluation. By quantitatively capturing mental health symptoms, our AI-COA™ models offer a consistent, bias-free assessment, enhancing the precision and reliability of clinical trials. This means significantly more powerful, efficient, and faster drug development processes, leading to improved patient care and significant public health advancements. 🌟 A Personal Milestone: As Founder & CEO, this milestone is very personal to me. It represents years of our team's dedication and the relentless pursuit of our mission to empower mental health care through precision, empathy, and innovation. 🙏 Heartfelt Thanks: A huge shoutout to our talented team at Deliberate AI, past and present -- your hard work and dedication have made this possible. Also, a special thanks to leading experts in the field, Maurizio Fava and René S. Kahn MD, PhD, for your statements emphasizing the significance of this milestone. 💼 To Our Investors and Future Partners: This achievement exemplifies our potential for growth and scalability in the clinical trials and healthcare sectors. Deliberate AI is not just innovating; we're leading the way in AI for mental health. We're enabling 3 transformative and reinforcing shifts: Advanced Diagnostics and Monitoring, Ambient Clinical Intelligence and Precision Therapy Enablement. Let’s connect to explore how we can drive the future of mental health together. 👀 Stay Tuned: The inclusion of AI in drug development and healthcare is just starting, as is our journey. Follow us here on LinkedIn and sign up for our newsletter to not miss out on more exciting updates coming soon! 📩 Newsletter Sign-Up: https://bit.ly/3SI0NYd 🤝 Join the Conversation: What do you think the future holds for AI in healthcare? What are some of your questions and considerations of the use of AI in late-stage Clinical Trials? Share your thoughts below! #DigitalHealth #HealthTech #Medtech #Multimodal #AI #PharmaInnovation #ClinicalTrials #Depression #Anxiety #AIEthics ##AIinHealthcare Mary Fortson, Nurah K., Kapildev Neupane, Rachna Saralkar, MD, MS, Katie Aafjes-van Doorn, Jeff Cohn, Marcelo Cicconet, Ben Barone, Jeremy Jones.

Excited to see the FDA's guidance on the use of Digital Health Technology (DHT) for Remote Data Acquistion in studies, reaching its final form since the initial draft was released in December 2021. This is a pivotal step in revolutionizing clinical trials, and pushing beyond traditional randomized controlled trials (RCTs) to bring safer, more effective diagnostics and therapies to patients faster — and ensuring they work in real-world settings as well. At Deliberate AI, we're at the forefront of transforming mental healthcare with our Ambient Multimodal AI technology. The continued regulatory support for Digital Health Technology is critical on our mission to empower mental health care through precision, empathy, and innovation. We're committed to shifting from one-size-fits-all treatments to personalized, effective care, revolutionizing mental health assessments and therapy. Stay tuned for a major announcement from us soon – we're just as excited about the future of healthcare innovation as you are! Learn more about Deliberate AI #DigitalHealth #FDA #ClinicalTrials #MentalHealthInnovation #HealthTech #AIinHealthcare #PrecisionMedicine #InnovationInHealth #DeliberateAI